BI-905711

This study is open to adults with advanced colorectal cancer or with advanced pancreatic cancer. The study has 2 parts. In the first part, participants with colorectal cancer get a medicine called BI 905711 combined with chemotherapy and bevacizumab. The purpose of the first part is to find the highest BI 905711 dose participants can tolerate. In the second part, participants with colorectal cancer or pancreatic cancer get BI 905711 combined with chemotherapy. Some participants also get bevacizumab. The second part tests whether BI 905711 makes tumours shrink. Participants get BI 905711, chemotherapy and bevacizumab about every 2 weeks as an infusion into a vein. Participants can stay in the study as long as they benefit from treatment and can tolerate it. The doctors regularly check the health of the participants and note any health problems that could have been caused by the study treatment. The doctors also monitor the size of the tumour.

Ia期： 探索BI 905711的安全性，并确定最大耐受剂量（MTD）;探索药代动力学/药效动力学和有效性，在未确定MTD的情况下为确定Ib期的潜在有效剂量范围提供指导 Ib期： 评价BI 905711在潜在有效剂量范围内的有效性和安全性，并确定RP2D（推荐的II期剂量）